- Home
- BRNS vs RAND Comparison
BRNS vs RAND Comparison
Compare BRNS & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- RAND
- Stock Information
- Founded
- BRNS 2016
- RAND 1969
- Country
- BRNS United Kingdom
- RAND United States
- Employees
- BRNS N/A
- RAND N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- RAND Finance: Consumer Services
- Sector
- BRNS Health Care
- RAND Finance
- Exchange
- BRNS Nasdaq
- RAND Nasdaq
- Market Cap
- BRNS 36.0M
- RAND 57.6M
- IPO Year
- BRNS 2021
- RAND N/A
- Fundamental
- Price
- BRNS $0.95
- RAND $16.67
- Analyst Decision
- BRNS Strong Buy
- RAND
- Analyst Count
- BRNS 1
- RAND 0
- Target Price
- BRNS $3.00
- RAND N/A
- AVG Volume (30 Days)
- BRNS 13.5K
- RAND 5.0K
- Earning Date
- BRNS 08-07-2025
- RAND 08-05-2025
- Dividend Yield
- BRNS N/A
- RAND 10.11%
- EPS Growth
- BRNS N/A
- RAND 39.77
- EPS
- BRNS N/A
- RAND 3.12
- Revenue
- BRNS $14,969,000.00
- RAND $8,499,970.00
- Revenue This Year
- BRNS N/A
- RAND N/A
- Revenue Next Year
- BRNS N/A
- RAND N/A
- P/E Ratio
- BRNS N/A
- RAND $5.23
- Revenue Growth
- BRNS 4381.74
- RAND 12.52
- 52 Week Low
- BRNS $0.64
- RAND $14.30
- 52 Week High
- BRNS $1.58
- RAND $31.89
- Technical
- Relative Strength Index (RSI)
- BRNS 57.55
- RAND 60.63
- Support Level
- BRNS $0.90
- RAND $16.26
- Resistance Level
- BRNS $1.05
- RAND $16.89
- Average True Range (ATR)
- BRNS 0.06
- RAND 0.41
- MACD
- BRNS 0.01
- RAND 0.21
- Stochastic Oscillator
- BRNS 71.96
- RAND 88.36
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.